UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Grover病(暂时性和持续性棘层松解性皮肤病)

Authors
Helge Riemann, MD
Whitney A High, MD
Section Editor
Robert P Dellavalle, MD, PhD, MSPH
Deputy Editor
Rosamaria Corona, MD, DSc
Translators
刘玲, 主治医师

引言

1970年，Ralph Grover报道了一项纳入6例患者的病例系列研究，这些患者在躯干均出现了瘙痒的丘疹和/或丘疱疹，并在数周内消退[1]。组织病理学分析显示其特征为表皮内棘层松解，Grover将本病命名为“暂时性棘层松解性皮肤病”。随后的一些报告描述该病常呈现慢性病程，但组织学改变基本一致，因此提出了“暂时性和持续性棘层松解性皮肤病”这一术语[2,3]。不过，“Grover病”这一名称仍在广泛使用。

流行病学

Grover病的患病率和发病率尚不十分明确。瑞士的一项研究显示，超过30,000例次皮肤活检中只有24例被诊断为Grover病[4]。

目前认为Grover病好发于40岁以上的白种人，并且男性发病率约为女性的1.6-2.1倍[5,6]。Grover病似乎不常发生于深肤色人群，但也有相关报道[5]。

病因学

Grover病的病因学不明。诱发该病活动的可疑因素包括热、出汗、日照、电离辐射、终末期肾病/血液透析以及机械性刺激或长期卧床[7]。

部分病例的Grover病与药物有关，例如复方磺胺多辛、利巴韦林、西妥昔单抗和白细胞介素-4[1,8-15]。一项纳入300例Grover病患者的病例系列研究报道，本病与其他同时存在的皮肤病相关，包括特应性皮炎、接触性皮炎和皮肤干燥症[5]。最后，较小型的病例系列研究详述了本病与坏疽性脓皮病、细菌和病毒感染的相关性，偶尔也描述了与恶性肿瘤有关[5,16]。

     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: 2017-06 . | This topic last updated: 2016-02-12.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Grover RW. Transient acantholytic dermatosis. Arch Dermatol 1970; 101:426.
  2. Simon RS, Bloom D, Ackerman AB. Persistent acantholytic dermatosis. A variant of transient acantholytic dermatosis (Grover disease). Arch Dermatol 1976; 112:1429.
  3. Heenan PJ, Quirk CJ. Transient acantholytic dermatosis. Br J Dermatol 1980; 102:515.
  4. Streit M, Paredes BE, Braathen LR, Brand CU. [Transitory acantholytic dermatosis (Grover disease). An analysis of the clinical spectrum based on 21 histologically assessed cases]. Hautarzt 2000; 51:244.
  5. Parsons JM. Transient acantholytic dermatosis (Grover's disease): a global perspective. J Am Acad Dermatol 1996; 35:653.
  6. Scheinfeld N, Mones J. Seasonal variation of transient acantholytic dyskeratosis (Grover's disease). J Am Acad Dermatol 2006; 55:263.
  7. Quirk CJ, Heenan PJ. Grover's disease: 34 years on. Australas J Dermatol 2004; 45:83.
  8. Hu CH, Michel B, Farber EM. Transient acantholytic dermatosis (Grover's disease). A skin disorder related to heat and sweating. Arch Dermatol 1985; 121:1439.
  9. Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol 1994; 12:1703.
  10. Casanova JM, Pujol RM, Taberner R, et al. Grover's disease in patients with chronic renal failure receiving hemodialysis: clinicopathologic review of 4 cases. J Am Acad Dermatol 1999; 41:1029.
  11. French LE, Piletta PA, Etienne A, et al. Incidence of transient acantholytic dermatosis (Grover's disease) in a hospital setting. Dermatology 1999; 198:410.
  12. Ott, A. Persistent acantholytic dermatosis in a patient with increased sensitivity to light. Zeitschrift fuer Hautkrankheiten 1993; 62:369.
  13. Antunes I, Azevedo F, Mesquita-Guimarães J, et al. Grover's disease secondary to ribavirin. Br J Dermatol 2000; 142:1257.
  14. Mahler SJ, De Villez RL, Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol 1993; 29:206.
  15. Tscharner GG, Bühler S, Borner M, Hunziker T. Grover's disease induced by cetuximab. Dermatology 2006; 213:37.
  16. Andersen BL. Pyoderma gangrenosum associated with transient acantholytic dermatosis (pemphigus erythematosus-like) and paraproteinemia. Acta Derm Venereol 1981; 61:77.
  17. Powell J, Sakuntabhai A, James M, et al. Grover's disease, despite histological similarity to Darier's disease, does not share an abnormality in the ATP2A2 gene. Br J Dermatol 2000; 143:658.
  18. Hashimoto K, Moiin A, Chang MW, Tada J. Sudoriferous acrosyringeal acantholytic disease. A subset of Grover's disease. J Cutan Pathol 1996; 23:151.
  19. Antley CM, Carrington PR, Mrak RE, Smoller BR. Grover's disease (transient acantholytic dermatosis): relationship of acantholysis to acrosyringia. J Cutan Pathol 1998; 25:545.
  20. Davis MD, Dinneen AM, Landa N, Gibson LE. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc 1999; 74:229.
  21. Weedon D. Skin Pathology, Churchill Livingstone, London 2002. p.297.
  22. Gilchrist H, Jackson S, Morse L, et al. Galli-Galli disease: A case report with review of the literature. J Am Acad Dermatol 2008; 58:299.
  23. Erös N, Kovács A, Károlyi Z. Successful treatment of transient acantholytic dermatosis with systemic steroids. J Dermatol 1998; 25:469.
  24. Keohane SG, Cork MJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995; 132:832.
  25. Mota AV, Correia TM, Lopes JM, Guimarães JM. Successful treatment of Grover's disease with calcipotriol. Eur J Dermatol 1998; 8:33.
  26. Hayashi H, Yokota K, Koizumi H, Shimizu H. Treatment of Grover's disease with tacalcitol. Clin Exp Dermatol 2002; 27:160.
  27. Dodd HJ, Sarkany I. Persistent acantholytic dermatosis. Clin Exp Dermatol 1984; 9:431.
  28. Helfman RJ. Grover's disease treated with isotretinoin. Report of four cases. J Am Acad Dermatol 1985; 12:981.
  29. Breuckmann F, Appelhans C, Altmeyer P, Kreuter A. Medium-dose ultraviolet A1 phototherapy in transient acantholytic dermatosis (Grover's disease). J Am Acad Dermatol 2005; 52:169.
  30. Paul BS, Arndt KA. Response of transient acantholytic dermatosis to photochemotherapy. Arch Dermatol 1984; 120:121.
  31. Liu S, Letada PR. Successful novel treatment of recalcitrant transient acantholytic dermatosis (Grover disease) using red light 5-aminolevulinic acid photodynamic therapy. Dermatol Surg 2013; 39:960.
  32. Norman R, Chau V. Use of etanercept in treating pruritus and preventing new lesions in Grover disease. J Am Acad Dermatol 2011; 64:796.